Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB; SIMCOMBIN study investigators. Sorensen PS, et al. Among authors: frederiksen jl. Lancet Neurol. 2011 Aug;10(8):691-701. doi: 10.1016/S1474-4422(11)70144-2. Lancet Neurol. 2011. PMID: 21742556 Clinical Trial.
Aggressive multiple sclerosis (1): Towards a definition of the phenotype.
Iacobaeus E, Arrambide G, Amato MP, Derfuss T, Vukusic S, Hemmer B, Tintore M, Brundin L; 2018 ECTRIMS Focused Workshop Group. Iacobaeus E, et al. Mult Scler. 2020 Jun 12;26(9):1352458520925369. doi: 10.1177/1352458520925369. Online ahead of print. Mult Scler. 2020. PMID: 32530385 Free PMC article.
Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis-A real-world evidence study.
Frederiksen JL, Massacesi L, Nielsen HH, Rini A, Baldi E, Mirabella M, Antonella FFM, Lus G, Paolicelli D, Kant M, Salemi G, Aguglia U, Comi C, De Riz M, Barcella V, Flemmen HØ, Protti A, Farbu E, van Exel J, Torkildsen Ø. Frederiksen JL, et al. Mult Scler Relat Disord. 2024 Dec 3;93:106214. doi: 10.1016/j.msard.2024.106214. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 39642455 Free article.
Detection of capillary abnormalities in early diabetic retinopathy using scanning laser ophthalmoscopy and optical coherence tomography combined with adaptive optics.
Torm MEW, Pircher M, Bonnin S, Johannesen J, Klefter ON, Schmidt MF, Frederiksen JL, Lefaudeux N, Andilla J, Valdes C, Loza-Alvarez P, Brea LS, De Jesus DA, Grieve K, Paques M, Larsen M, Gocho K. Torm MEW, et al. Among authors: frederiksen jl. Sci Rep. 2024 Jun 11;14(1):13450. doi: 10.1038/s41598-024-63749-7. Sci Rep. 2024. PMID: 38862584 Free PMC article.
Age-related decline in cerebral oxygen consumption in multiple sclerosis.
Knudsen MH, Vestergaard MB, Lindberg U, Simonsen HJ, Frederiksen JL, Cramer SP, Larsson HB. Knudsen MH, et al. Among authors: frederiksen jl. J Cereb Blood Flow Metab. 2024 Jun;44(6):1039-1052. doi: 10.1177/0271678X231224502. Epub 2024 Jan 8. J Cereb Blood Flow Metab. 2024. PMID: 38190981
Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects.
Samadzadeh S, Olesen MN, Wirenfeldt M, Möller S, Misu T, Soelberg K, Frederiksen JL, Heegaard S, Mariotto S, Fujihara K, Ruprecht K, Andersen TL, Marignier R, Lillevang ST, Flanagan EP, Pittock SJ, Kim HJ, Bennett JL, Paul F, Sorensen GL, Weinshenker BG, Lassmann H, Asgari N. Samadzadeh S, et al. Among authors: frederiksen jl. Mult Scler. 2023 Dec;29(14):1721-1735. doi: 10.1177/13524585231200720. Epub 2023 Oct 13. Mult Scler. 2023. PMID: 37830484 Free PMC article.
164 results